Experimental COVID-19 drug fails to prevent respiratory failure in High-Risk patients

NCT ID NCT04393038

Terminated Disease control Sponsor: Abivax S.A. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called ABX464 in 509 high-risk COVID-19 patients aged 65 and older, or those 18+ with risk factors like obesity or diabetes. The goal was to see if the drug could reduce inflammation and prevent the need for high-flow oxygen or a breathing machine. Unfortunately, the trial was stopped early because the drug did not show enough benefit compared to a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ABX464 (an experimental anti-inflammatory drug)
What this could lead to: If it had worked, this could have pointed toward a treatment to prevent severe breathing problems in older or high-risk COVID-19 patients.
What could go wrong: The trial was stopped early because it was not showing enough benefit. It was also a mid-stage study, so even positive results would have needed more testing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 acute respiratory failure prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19

Contacts and locations

Locations

Asklepios Klinik Altona

Hamburg, 22763, Germany
Asklepios Klinik St. Georg

Hamburg, 20099, Germany
Centre Hospitalier Départemental de Vendée

La Roche-sur-Yon, 85000, France
Centre Hospitalier Universitaire de Nice

Nice, 06003, France
Centre hospitalier Saint Pierre

Brussels, 1000, Belgium
Centro Oncológico de Roraima - CECOR - NAP

Boa Vista, Roraima, 69310-000, Brazil
Centro de Prevención y Rehabilitación de Enfermedades Pulmon

Nuevo León, 64460, Mexico
Conjunto Hospitalar do Mandaqui

São Paulo, 02401-400, Brazil
Consultorio médico

Mérida, Yucatán, 97070, Mexico
Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico - Infectious Diseases

Milan, Lombardy, 20122, Italy
Fundacao de Medicina Tropical Doutor Heitor Vieira Dourado - Instituto de Pesquisa Clínica Carlos Borborema

Manaus, Amazonas, 69040-000, Brazil
H.G.U. Alicante

Alicante, 03010, Spain
Hospital Universitari Germans Trias i Pujol

Badalona, Barcelona, 08916, Spain
Hospital Universitario Infanta Leonor

Madrid, 28031, Spain
Hospital das Clinicas da FMUSP

São Paulo, São Paulo, 05403-000, Brazil
Hospital de La Princesa

Madrid, 28006, Spain
Hospital del Mar

Barcelona, 08003, Spain
Hôpital Erasme

Brussels, 1070, Belgium
Hôpital Nord

Amiens, 80000, France
Hôpital Saint-Antoine

Paris, 75571, France
Instituto Nacional de Infectologia Evandro Chagas - FIOCRUZ Rio de Janeiro

Rio de Janeiro, 21040-360, Brazil
Ospedale A. Manzonidi Lecco - ASST Lecco

Lecco, 23900, Italy
Ospedale Luigi Sacco, AO-PU

Milan, Lombardy, 20157, Italy
Ospedale Niguarda

Milan, 20162, Italy
Ospedale San Paolo

Milan, Lombardy, 20142, Italy
Ospedale di Vittorio Veneto - Medecina generale

Vittorio Veneto, Treviso, 31029, Italy
Royal Free Hospital

London, NW3 2QG, United Kingdom
UZ Gent

Ghent, 9000, Belgium
Universitätsklinikum Bonn

Bonn, North Rhine-Westphalia, 53127, Germany
Universitätsmedizin Mannheim Ruprecht-Karls-Universität Heid

Mannheim, Baden-Wurttemberg, 68167, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.